Trial Profile
A Study of the Efficacy and PK/PD Relationship of Monotherapy MORAb-004 in Subjects With Metastatic Melanoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Sep 2021
Price :
$35
*
At a glance
- Drugs Ontuxizumab (Primary)
- Indications Malignant melanoma; Skin cancer
- Focus Proof of concept; Therapeutic Use
- Sponsors Morphotek
- 30 Apr 2020 Status changed from active, no longer recruiting to completed.
- 15 Apr 2019 Planned End Date changed from 31 Jan 2019 to 31 Jan 2020.
- 02 Jan 2019 Planned End Date changed from 1 Dec 2017 to 31 Jan 2019.